US EditionPublished • loading... • Updated
Biopharma Giant Draws Spotlight With High-Stakes Investor Talks on MASH Breakthrough
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Biopharma Giant Draws Spotlight With High-Stakes Investor Talks on MASH Breakthrough
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), the company behind the first FDA- and European Commission–approved drug for MASH, will spotlight its flagship therapy in a pair of fireside chats at major investor conferences next week. The biopharmaceutical firm is scheduled to present at the 8th Annual Evercore Healthcare Conference on Tuesday, Dec. 2, 2025, at 4:15 p.m. ET, followed by an appearance at the Piper Sandler 37th A…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
